# TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis

> **NCT00023335** · PHASE3 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 1000 (—)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Rifapentine
- **DRUG:** Isoniazid

## Key facts

- **NCT ID:** NCT00023335
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-04
- **Primary completion:** —
- **Final completion:** 2001-03
- **Target enrollment:** 1000 (—)
- **Last updated:** 2005-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023335, "TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00023335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*